Grant Eye Point Pharmaceuticals, Inc. Transaction History
Grant
- $170 Million
- Q1 2025
A detailed history of Grant transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Grant holds 36,620 shares of EYPT stock, worth $500,229. This represents 0.12% of its overall portfolio holdings.
Number of Shares
36,620
Previous 36,640
0.05%
Holding current value
$500,229
Previous $272,000
27.21%
% of portfolio
0.12%
Previous 0.15%
Shares
2 transactions
Others Institutions Holding EYPT
# of Institutions
159Shares Held
67.1MCall Options Held
214KPut Options Held
994K-
Cormorant Asset Management, LP Boston, MA8.33MShares$114 Million7.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$92.9 Million2.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.8MShares$92.9 Million0.11% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.6MShares$62.8 Million0.09% of portfolio
-
Franklin Resources Inc San Mateo, CA4.3MShares$58.8 Million0.01% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $465M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...